Ansell Ltd., a global leader in protection solutions, has today introduced a ground-breaking new SENSOPRENE™ formulation, with the launch of its GAMMEX® Non-Latex Accelerator-Free Sensitive surgical glove. SENSOPRENE™ formulation is up to 30 per cent thinner than standard surgical gloves to provide an unprecedented level of sensitivity and comfort for healthcare workers worldwide.
Not only does SENSOPRENE™ technology deliver market-leading sensitivity, it also provides advanced allergy protection. Free of both latex proteins and chemical accelerators, the SENSOPRENE™ formulation reduces the risk of both Type I (latex) and Type IV (chemical) allergies. Clinical evidence reveals that 33 per cent of glove-related allergic reactions in the medical sector are chemical-based while 17 per cent are latex-related.
The GAMMEX® Non-Latex Accelerator-Free Sensitive surgical glove with SENSOPRENE™ is a unique and complete solution, suitable for any surgical need and all allergenic profiles. It addresses key end-user requirements - fit, comfort, grip, strength, resistance, as well as providing unrivalled sensitivity and allergy protection.
Commenting on the new SENSOPRENE™ formulation, Anthony B. Lopez, President and General Manager of Ansell's Medical Global Business Unit said,
"For over 100 years, Ansell has delivered market-leading solutions, to support and empower healthcare workers and protect patients worldwide. An approach based on innovation and continual technological advancement is key to our business. We were the first company to introduce an accelerator-free surgical glove and, with SENSOPRENE™, we are again setting a new standard for allergy management in the healthcare industry."
He continued, "With more than 100 million pairs of GAMMEX® surgical gloves used annually in hospitals worldwide, our insight is second to none. We know and anticipate our end-users' requirements and continually strive to not just meet, but exceed them."
SOURCE Ansell Healthcare Europe nv